Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

Rhea-AI Summary

Alector (Nasdaq: ALEC) appointed Neil Berkley as Chief Financial Officer effective December 10, 2025. Berkley has served as Chief Business Officer since March 2024 and as Interim CFO since June 2025, and will continue to serve as CBO.

He brings more than two decades of experience in corporate strategy, finance, business development, fundraising, and operations across large pharma and biotech. Since joining in 2024 he helped advance strategic priorities, partnerships, and value-creation initiatives while supporting the company’s pipeline and ABC-enabled programs.

Positive

• Permanent CFO appointment effective December 10, 2025
• Continuity: served as Interim CFO since June 2025
• Dual role retained as CFO and Chief Business Officer
• Experience: more than two decades in biotech finance and strategy
• Track record at Alector: supported partnerships and value-creation since 2024

Negative

• None.

Key Figures

CBO start date March 2024 Neil Berkley began serving as Chief Business Officer

Interim CFO start June 2025 Berkley added Interim Chief Financial Officer role

CFO effective date December 10, 2025 Appointment as Chief Financial Officer became effective

Executive experience More than two decades Berkley’s experience leading strategy, finance, BD, and operations

Market Reality Check

$1.49 Last Close

Volume Volume 4,988,286 is 2.81x the 20-day average of 1,774,807, signaling elevated interest ahead of this leadership update. high

Technical Shares at $1.46 are trading below the 200-day MA of $1.73 and about 57.06% under the 52-week high.

Peers on Argus

ALEC gained 12.31% while close biotech peers were mixed, with one modest gainer (FHTX +0.67%) and several decliners (e.g., OMER -4.51%), indicating a stock-specific move around this management change rather than a broad sector swing.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 01	Conference participation	Neutral	-7.3%	Announced participation in Bank of America CNS Therapeutics Conference webcast.
Nov 06	Earnings update	Neutral	+3.6%	Reported Q3 2025 results, ABC platform progress, and cash runway into 2027.
Oct 21	Trial results & cuts	Negative	-3.0%	Phase 3 latozinemab failed clinical endpoint; workforce reduced and studies halted.
Sep 16	R&D event	Positive	-6.8%	Announced virtual R&D event highlighting PGRN franchise and ABC programs.
Aug 28	Investor conferences	Neutral	-0.4%	Planned participation in multiple September healthcare investor conferences.

Pattern Detected

Recent news reactions skew negative, especially around conference and R&D events, while clearly negative clinical outcomes aligned with a modest decline. Positive or neutral corporate updates have not consistently produced sustained strength.

Recent Company History

Over the last several months, ALEC’s trajectory has been shaped by mixed catalysts. A failed Phase 3 latozinemab trial and a major workforce reduction on Oct 21, 2025 were followed by Q3 results on Nov 6, 2025 that highlighted $291.1M in cash and continued investment in the ABC platform. Multiple conference and R&D events in August–December saw mostly negative price reactions despite being largely informational. Today’s appointment of Neil Berkley as CFO and continuation as CBO fits into this broader period of strategic refocusing after the latozinemab setback.

Market Pulse Summary

This announcement formalizes Neil Berkley’s transition from interim to permanent CFO while he continues as CBO, consolidating financial and business leadership during a key period for Alector’s neurodegeneration pipeline. In recent months the company managed a failed Phase 3 trial, a large workforce reduction, and a renewed focus on its ABC-enabled programs. Investors may watch how this leadership structure supports capital allocation, partnership strategy, and future clinical milestones highlighted in prior earnings and regulatory filings.

Key Terms

neurodegeneration medical

"developing therapies to counteract the devastating progression of neurodegeneration"

Neurodegeneration is the gradual damage and loss of nerve cells in the brain and nervous system, producing symptoms such as memory decline, impaired movement, or thinking problems. Think of it like electrical wiring in a house slowly fraying, which undermines how the system runs. For investors it matters because it drives demand for diagnostics, treatments and long-term care, influences regulatory risk and trial outcomes, and can significantly affect the value of health-care and biotech companies.

neurodegenerative diseases medical

"advancing transformative therapies to patients with neurodegenerative diseases"

Neurodegenerative diseases are conditions where brain or nerve cells progressively lose function and die, causing symptoms like memory loss, movement problems, or cognitive decline — think of the brain’s wiring slowly wearing out. Investors care because these illnesses create sustained demand for treatments, diagnostics, and long-term care, drive regulatory decisions and clinical-trial milestones that move stock prices, and concentrate both high development risk and the potential for large financial returns if effective therapies are approved.

AI-generated analysis. Not financial advice.

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector’s Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO.

“Neil has demonstrated exceptional leadership, judgment, strategic insight, and an unwavering commitment to Alector’s mission,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. “His deep understanding of our science and business drivers—combined with his operational and financial acumen—makes him uniquely suited to assume the CFO role as we advance through an important period for the company.”

Mr. Berkley is an accomplished biotech executive with more than two decades of experience leading corporate strategy, finance, business development, and operations across both early- and late-stage companies. He brings broad experience across large pharmaceutical, midsize biotechnology, and emerging biotech companies, and has supported a wide range of strategic and transactional partnerships throughout his career. Since joining Alector in 2024, he has played a key role in advancing the company’s strategic priorities, strengthening partnerships, and supporting key value-creation initiatives across the organization. He also brings experience in financing and fundraising, investor engagement, and corporate development, along with a background that includes founding two companies and serving on the boards of multiple biotech organizations.

“I’m honored to serve Alector in this capacity,” said Berkley. “It is a privilege to work with such a talented team dedicated to advancing transformative therapies to patients with neurodegenerative diseases. I look forward to continuing to support the company’s scientific and corporate priorities, including the advancement of our promising pipeline and the ongoing development of our ABC-enabled programs.”

About Alector
Alector is a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease, Parkinson's disease, and frontotemporal dementia. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.

Alector Contacts:
Argot Partners (media)
David Rosen
(212) 600-1494
alector@argotpartners.com

Argot Partners (investors)
Laura Perry
(212) 600-1902
alector@argotpartners.com

FAQ

When did Alector appoint Neil Berkley as CFO (ALEC)?

Neil Berkley was appointed CFO effective December 10, 2025.

What roles will Neil Berkley hold at Alector (ALEC) after December 2025?

He will serve as Chief Financial Officer and continue as Chief Business Officer.

How long has Neil Berkley worked at Alector (ALEC) before becoming CFO?

Berkley joined Alector as Chief Business Officer in March 2024 and was Interim CFO since June 2025.

What experience does Neil Berkley bring to the CFO role at Alector (ALEC)?

He has more than two decades of experience in corporate strategy, finance, business development, fundraising, and operations across pharma and biotech.

Will Neil Berkley continue to handle business development at Alector (ALEC)?

Yes. He will continue to serve as Chief Business Officer while holding the CFO role.

Does the press release mention financial guidance or metrics tied to the CFO appointment for ALEC?

No. The announcement focuses on the appointment, roles, and Berkley’s background without financial guidance or metrics.